This is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist initially approved for type 2 diabetes under the trade names Ozempic® (injectable, 2017) and Rybelsus® (oral, 2019). This evidence concerns the gene GCG and type 2 diabetes mellitus.